Form 4: Palisade Bio CEO Mitchell Jones Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
CEO Mitchell Jones reports the vesting and settlement of restricted stock units (RSUs) and subsequent tax withholding, resulting in changes to his beneficial ownership of Palisade Bio stock.
Summary
- Mitchell Jones, CEO, CFO, and Director of Palisade Bio, Inc., reported transactions related to the vesting and settlement of restricted stock units.
- On May 6, 2024, 304 shares of common stock were issued upon the vesting of RSUs granted on September 5, 2023.
- Additionally, 90 shares were withheld to cover tax obligations related to this vesting.
- On the same date, 156 shares of common stock were issued upon the vesting of RSUs granted on November 21, 2023.
- 47 shares were withheld to cover tax obligations related to the vesting of these RSUs.
- Following these transactions, Jones directly owns 833 shares of Palisade Bio common stock and 4,290 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Future Outlook
The remaining restricted stock units will continue to vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer at the time of vesting.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings and transactions of company insiders.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units (RSUs) that vest over time, aligning executive interests with long-term shareholder value.
- Tax withholding upon vesting of RSUs is a standard practice to cover income tax obligations.
- Similar filings are regularly made by executives at comparable companies like BioCryst Pharmaceuticals and Mirati Therapeutics, reflecting similar compensation structures.
Stakeholder Impact
- Shareholders are informed about changes in the beneficial ownership of a key executive.
- The transactions have a minor dilutive effect due to the issuance of new shares upon RSU vesting.
Key Dates
| Date | Description |
|---|---|
| 09/05/2023 | Grant date of restricted stock units, where 304 units vested on May 6, 2024, and the remaining will vest quarterly over three years. |
| 11/21/2023 | Grant date of restricted stock units, where 156 units vested on May 6, 2024, and the remaining will vest quarterly over three years. |
| 05/06/2024 | Date of transaction: Vesting and settlement of restricted stock units and tax withholding. |
| 05/08/2024 | Date of signature for the SEC Form 4 filing. |
Keywords
Palisade Bio, Mitchell Jones, SEC Form 4, Beneficial Ownership, Restricted Stock Units, RSU Vesting, Tax Withholding, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.